Researchers in Germany studied more than 400 patients who suffer from type-2 diabetes. Half received one injection of Glargine, a long-acting form of insulin. The other group received three daily injections of Lispro, a fast-acting insulin. To track how well blood-sugar was controlled, they measured the concentration of hemoglobin A1C in the blood. At the end of the study, they found similar reductions in the hemoglobin.
This study appears in The Lancet.
